UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of June 2017
Commission File Number:001-36697
DBV TECHNOLOGIES S.A.
(Translation of registrant’s name into English)
177-181 avenue Pierre Brossolette
92120 Montrouge France
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
☒ Form20-F ☐ Form40-F
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
EXHIBIT LIST
Exhibit | Description | |
| 99.1 | Press Release dated June 15, 2017. | |
| 99.2 | Press Release dated June 15, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DBV TECHNOLOGIES S.A. | ||||||
| Date: June 15, 2017 | By: | /s/ David Schilansky | ||||
| Name David Schilansky | ||||||
| Title: Chief Operating Officer | ||||||
Exhibit 99.1
AMF REGULATED INFORMATION
Montrouge, France, June 15, 2017
DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting
Shareholders approve all proposed resolutions
DBV Technologies (Euronext: DBV – ISIN: FR0010417345—Nasdaq Stock Market: DBVT) today held its Ordinary and Extraordinary General Meeting, which was chaired by Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies.
At the General Meeting, the Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions are posted on the Investor Relations section of the Company’s website,http://www.dbv-technologies.com/en/investor-relations.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered andnon-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a humanproof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representingone-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website:www.dbv-technologies.com
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman@dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia@webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline@alizerp.com
Exhibit 99.2
Press Release
Montrouge, France, June 15, 2017
DBV Technologies Announces
Appointment of Julie O’Neill to Board of Directors
DBV Technologies (Euronext: DBV – ISIN: FR0010417345—Nasdaq Stock Market: DBVT) announced today that Julie O’Neill has been appointed to the Company’s Board of Directors, effective immediately pursuant to her election at the Company’s Ordinary and Extraordinary General Meeting in Montrouge, France. With this addition, DBV’s Board now comprises eight directors.
Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies, said:“Ms. O’Neill is an accomplished leader who brings her vast experience and knowledge of the biopharmaceutical industry to our Board. Her complementary expertise in manufacturing and quality operations will enable her to make significant contributions during this pivotal time for the Phase III Viaskin Peanut development program and DBV.”
Ms. O’Neill is expected to serve on the Board for a period of two years. She is currently Executive Vice President, Global Operations of Alexion, responsible for global manufacturing operations, as well as Alexion’s complete supply chain and quality operations. Before joining Alexion, she was Vice President of Operations and General Manager for Ireland at Gilead. Earlier in her career, Ms. O’Neill held leadership positions in operations, manufacturing and quality functions at Burnil Pharmacies and Helsinn Birex Pharmaceuticals. She also serves as Chairperson for the National Standards Authority of Ireland and is a member of the Governing Body of University College Cork.
“I am honored and excited to join the Board of DBV,” saidMs. Julie O’Neill.“Throughout my career, I have held leadership positions in biopharmaceutical operations, manufacturing, supply chain and quality control, and I look forward to working with the Board and management team in their mission to bring safe and effective treatments to patients with food allergies and other unmet medical needs.”
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered andnon-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a humanproof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representingone-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website:www.dbv-technologies.com
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman@dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia@webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline@alizerp.com